Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol
Journal of Antimicrobial Chemotherapy · 02.12.2025 · 80 (12) · 3297-3305
DOI: 10.1093/jac/dkaf364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 28.10.2025. Verfasst von Inès Rezzoug und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bacteriology-Hygiene, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents, beta-Lactamases, Cephalosporins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: ADVANZ PHARMA.
Abstract (Originalsprache)
Background and objectives Carbapenem-resistant Enterobacterales (CRE) that do not produce carbapenemases (non-CPE) are increasingly reported worldwide and represent a major therapeutic challenge. These strains are typically resistant to carbapenems due to the combined effects of ESBL and/or AmpC production and reduced outer membrane permeability. However, data on their susceptibility to new antibiotics and β-lactam/β-lactamase inhibitor (BL/BLI) combinations remain limited. This study aimed to evaluate the in vitro activity of new antibiotics and BL/BLI combinations against CR non-CPE isolates.
Methods
MICs of ceftazidime–avibactam, cefepime–enmetazobactam, cefepime–taniborbactam, cefepime–zidebactam, imipenem–relebactam, meropenem–vaborbactam, aztreonam–avibactam, and cefiderocol were determined by the broth microdilution for 151 CR non-CPE isolates collected between 2024 and January 2025 at the French National Reference Center. The collection included ESBL producers (n = 33), AmpC producers (n = 79), and ESBL/AmpC co-producers (n = 29).
Results
Overall susceptibility rates were as follows: cefepime–zidebactam (97.4%), aztreonam–avibactam (92.7%), ceftazidime–avibactam (91.4%), meropenem–vaborbactam (91.3%), imipenem–relebactam (88.7%), cefiderocol (86.8%), cefepime–taniborbactam (82.1%), and cefepime–enmetazobactam (68.9%). Susceptibility varied according to the resistance mechanisms. Among ESBL producers, CTX-M-33-producing strains exhibited higher MICs than CTX-M-15 producers. Among AmpC producers, no specific high-risk AmpC type was associated with higher MICs, but Klebsiella aerogenes isolates exposed higher MICs than Enterobacter cloacae complex isolates.
Conclusions
CR non-CPE exhibit heterogeneous resistance profiles, especially in ESBL/AmpC co-producers and CTX-M-33-producing isolates. While cefepime–zidebactam, imipenem–relebactam, and cefiderocol were the most active agents, susceptibility testing remains essential to guide therapy in this emerging and neglected bacterial group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bacteriology-Hygiene, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
- INSERM UMR 1184, Paris-Saclay University, Le Kremlin-Bicêtre, France.
- French National Reference Center for Antibiotic Resistance, Le Kremlin-Bicêtre, France.
- Paris-Saclay University, Faculty of Medicine, Le Kremlin-Bicêtre, France.
ORCID-Profile: Laurent Dortet
Förderung
- ADVANZ PHARMA
Zitieren
APA
Rezzoug, I., Ouacel, K., Droit, T., Ronsin, S., Bonnin, R. A., Jousset, A. B., Latour, L., Dortet, L., & Emeraud, C. (2025). Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol. Journal of Antimicrobial Chemotherapy, 80(12), 3297-3305. https://doi.org/10.1093/jac/dkaf364
Vancouver
Rezzoug I, Ouacel K, Droit T, Ronsin S, Bonnin RA, Jousset AB, et al. Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol. Journal of Antimicrobial Chemotherapy. 2025;80(12):3297-3305. doi:10.1093/jac/dkaf364
BibTeX
@article{Rezzoug2025,
author = {Rezzoug, Inès and Ouacel, Kenza and Droit, Thomas and Ronsin, Sarah and Bonnin, Rémy A and Jousset, Agnès B and Latour, Lena and Dortet, Laurent and Emeraud, Cécile},
title = {Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales : an in vitro evaluation of novel β-lactam/β-lactamase inhibitor combinations and cefiderocol},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {12},
pages = {3297--3305},
doi = {10.1093/jac/dkaf364}
}
EUVIMED